The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat
Author(s): ,
Jason Grebely
Affiliations:
The Kirby Institute, UNSW Sydney, Sydney, Australia
,
Gregory J. Dore
Affiliations:
The Kirby Institute, UNSW Sydney, Sydney, Australia
,
Alessio Aghemo
Affiliations:
Department of Biomedical Sciences, Humanitas University, Humanitas Clinical and Research Center, Rozzano, Italy
,
Jeffrey V. Lazarus
Affiliations:
CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
,
Jean-Michel Pawlotsky
Affiliations:
INSERM U955, Créteil, France
Alison D. Marshall
Affiliations:
The Kirby Institute, UNSW Sydney, Sydney, Australia
Corresponding author. Address: Viral Hepatitis Clinical Research Program, The Kirby Institute, UNSW Sydney, Sydney, Australia. Tel.: +61 2 9385 9960; fax: +61 2 9385 0876.
EASL LiverTree™. D. Marshall A. Nov 1, 2018; 256716
Alison D. Marshall
Alison D. Marshall

Access to this content is an EASL members and LiverTree™ Privileged Users benefit.

Journal Abstract
References
Discussion Forum (0)
Rate & Comment (0)
Summary

Of ∼10.2 million people with chronic HCV infection in Europe, 6.7 million live in Eastern Europe, 2.3 million in Western Europe and 1.2 million in Central Europe.

HCV transmission continues to occur in parallel with an increasing HCV-related liver disease burden, the result of an ageing population infected during peak HCV epidemics decades earlier. In 2016, the World Health Organization set targets to eliminate HCV infection as a major public health threat by 2030. Across Europe, an estimated 36% of those living with chronic HCV infection have been diagnosed and ∼5% have been treated. A major barrier to enhancing HCV treatment uptake has been restrictions set by payers, including national governments and others, in response to the initially high list prices of direct-acting antiviral (DAA) therapies. The aims of this article are to discuss DAA restrictions in Europe, why DAA restrictions are still in place, what has facilitated the removal of DAA restrictions, and what challenges remain as we attempt to eliminate HCV as a major public health threat in the region by 2030.

Keyword(s)
Hepatitis C virus, Access, Elimination, Fibrosis, General practitioners, People who use drugs, Europe
[2]. B. Hajarizadeh - Epidemiology and natural history of HCV infection
[3]. E. Gane - Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2
[4]. F. Negro - Epidemiology of hepatitis C in Europe
[5]. H. Razavi - The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
[6]. M. Cornberg - A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
[7]. World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. June 2016. (accessed May 21, 2017).
[8]. Polaris Observatory HCV Collaborators. Countries on track to achieve WHO elimination targets. [cited; Available from: (accessed July 10, 2018).
[9]. X. Forns - Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial
[10]. D. Wyles - Glecaprevir/Pibrentasvir for HCV genotype 3 patients with cirrhosis and/or prior treatment experience: a partially randomized phase III clinical trial
[11]. J.J. Feld - Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection
[12]. G.J. Dore - Hepatitis C virus therapeutic development: in pursuit of “perfectovir”
[13]. E. Gane - Glecaprevir and Pibrentasvir in patients with HCV and severe renal impairment
[14]. O. Falade-Nwulia - Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review
[15]. H. Wedemeyer - Estimates on HCV disease burden worldwide – filling the gaps
[16]. H. Wedemeyer - Strategies to manage hepatitis C virus (HCV) disease burden
[17]. A.A. John-Baptiste - Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C
[18]. Z. Younossi - Systematic review: patient-reported outcomes in chronic hepatitis C–the impact of liver disease and new treatment regimens
[19]. A.J. van der Meer - Reversion of disease manifestations after HCV eradication
[20]. J. Grebely - What is killing people with hepatitis C virus infection?
[21]. B. Simmons - Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response
[22]. Z. Younossi - Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden
[23]. N. Scott - Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model
[24]. N.K. Martin - Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals
[25]. V. Saraswat - Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2
[26]. V. Liakina - Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 3
[27]. P. Bruggmann - Historical epidemiology of hepatitis C virus (HCV) in selected countries
[28]. J.V. Lazarus - Are the testing needs of key European populations affected by hepatitis B and hepatitis C being addressed? A scoping review of testing studies in Europe
[29]. H. Razavi - Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study
[30]. A.D. Marshall - Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study
[31]. S. Barua - Restrictions for Medicaid reimbursement of Sofosbuvir for the treatment of hepatitis C virus infection in the United States
[32]. A.D. Marshall - Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe
[33]. K. Ooka - Medicaid reimbursement for oral direct antiviral agents for the treatment of chronic hepatitis C
[34]. J.V. Lazarus - Restrictions on access to direct-acting antivirals for people who inject drugs: the European Hep-CORE study and the role of patient groups in monitoring national HCV responses
[36]. Government of British Columbia. More patients to benefit from hepatitis C treatments. News Release. February 21, 2017. [cited; Available from: (accessed October 20, 2017).
[37]. The Globe and Mail. Deal reduces price of life-saving hepatitis C drugs for Canadians. February 21, 2017. [cited; Available from: (accessed October 20, 2017).
[38]. 'Huge move forward' means more patients will be cured of hepatitis C, Ottawa doctor says. Elizabeth Payne. The Ottawa Citizen. March 8, 2018. [cited; Available from: (accessed April 19, 2018).
[39]. Quebec expands patient access to chronic hepatitis C therapies. Gilead Sciences, Inc., March 13, 2018. [cited; Available from: (accessed April 19, 2018).
[40]. N.S. Reau - Sticker shock and the price of new therapies for hepatitis C: is it worth it?
[41]. T.D. Szucs - The enigma of value: in search of affordable and accessible health care
[42]. S.B. Trooskin - Access to costly new hepatitis C drugs: medicine, money, and advocacy
[43]. C. Campillo-Artero - The merry-go-round of approval, pricing and reimbursement of drugs against the Hepatitis C virus infection in Spain
[44]. S. Iyengar - Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis
[45]. L.A. Kondili - Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort
[46]. J. Grebely - Excluding people who use drugs or alcohol from access to hepatitis C treatments – Is this fair, given the available data?
[47]. D.A. Asch - Rationing by any other name
[48]. B.J. Russell - Health-care rationing: critical features, ordinary language, and meaning
[49]. N.K. Martin - Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation
[50]. C. Zahnd - Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men
[51]. A.J. Leidner - Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease
[52]. S.H. Mehta - Doing the math on hepatitis C virus treatment
[53]. B. Hajarizadeh - Uptake of direct acting antiviral treatment for chronic hepatitis C in Australia
[54]. A.L. Mouterde - Hepatitis C: how has France limited the expenses related to new treatments?
[55]. L'Agenzia Italiana del Farmaco. Anti-HCV drugs: levels reached by price / volume agreements that allow reimbursement to Regions (12/30/2016). 2016 [cited; Available from: (accessed 2018 March 1).
[56]. A.K. Asher - Clinicians' views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs
[57]. J. Grebely - Direct-acting antiviral agents for HCV infection affecting people who inject drugs
[58]. L. Boglione - Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study
[59]. J. Bouscaillou - Effectiveness of DAA-based treatment of HCV in active people who inject drugs living in middle income countries (MIC): the results of a prospective cohort study in Tbilisi, Georgia
[60]. J. Grebely - Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial
[61]. G.J. Dore - Elbasvir-Grazoprevir to treat hepatitis C virus infection in persons peceiving opioid agonist therapy: a randomized trial
[62]. N. Scott - Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia
[63]. N.K. Martin - Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility
[64]. J. Grebely - Recommendations for the management of hepatitis C virus infection among people who inject drugs
[65]. World Health Organization. Status report on alcohol and health in 35 European countries. 2013 [cited; Available from: (accessed February 25, 2018).
[66]. World Health Organization. Global status report on alcohol and health. 2014 [cited; Available from: (accessed February 26, 2018).
[67]. M. Alavi - The contribution of alcohol-use disorder to decompensated cirrhosis among people with hepatitis C: an international study
[68]. G.J. Dore - Hepatitis C disease burden and strategies to manage the burden
[69]. S. Kattakuzhy - Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial
[70]. S. Arora - Outcomes of treatment for hepatitis C virus infection by primary care providers
[71]. A.J. Wade - Aiming for elimination: outcomes of a consultation pathway supporting regional general practitioners to prescribe direct acting antiviral therapy for hepatitis C
[72]. P. Bruggmann - Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all
[73]. G. Sander - Overview of harm reduction in prisons in seven European countries
[74]. The Boston Consulting Group and Gore C, Lazarus, JV and Baptista Leite, R. Road to Elimination. Barriers and best practices in hepatitis C management. Overview of the status of HCV care in Europe and Australia. July 2017 [cited; Available from: (accessed December 6, 2017).
[75]. S. Christensen - Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: still a concern in clinical practice?
[76]. J.J. Feld - Second generation direct-acting antivirals – do we expect major improvements?
[77]. J.M. Pawlotsky - Drugs: is next generation the last generation?
[78]. J. Chhatwal - Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA
[79]. World Health Organization. Regional committee for Europe 66th session. Action plan for the health sector response to viral hepatitis in the WHO European Region. Copenhagen, Denmark, September 12–15, 2016 [cited; Available from: (accessed June 23, 2017).
[80]. J.V. Lazarus - HEP-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017
[81]. B.R. Yehia - The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis
[82]. N. Scott - Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade
[83]. N.Z. Janjua - The population level cascade of care for hepatitis C in British Columbia, Canada: the BC Hepatitis Testers Cohort (BC-HTC)
[84]. J. Grebely - Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study
[85]. J. Grebely - Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis
[86]. World Health Organization. Global Hepatitis Report, 2017. [cited; Available from: (accessed January 5, 2018).
[87]. G. Dusheiko - Hepatitis C in the EU: setting the terms for elimination
[88]. European Liver Patients Association. The 2016 Hep-Core Report. Monitoring the implementation of hepatitis B and C policy recommendations in Europe. March 2017. [cited; Available from: (accessed May 30, 2017).
Code of conduct/disclaimer available in General Terms & Conditions

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies